The recent cavalcade of biotech deals continued Friday morning, when Bristol Myers Squibb said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback